Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intestinal microbiota transplantation (Zhongshan Hospital Xiamen University)
- Development stage
- Unknown
- Lead developer
- Zhongshan Hospital, Xiamen University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Intestinal microbiota transplantation (IMT), also known as fecal microbiota transplantation (FMT), is an investigational biologic therapy being developed by Zhongshan Hospital Xiamen University for the treatment of chronic hepatitis B (CHB). The intervention involves the transfer of viable commensal gut bacteria from healthy donor fecal samples to patients with CHB, typically those already receiving long-term antiviral therapy. The therapeutic rationale is based on the gut-liver axis, where restoring gut microbiota balance (correcting dysbiosis) is hypothesized to modulate the host's immune response, potentially leading to HBeAg clearance and seroconversion. Clinical studies evaluate the efficacy of IMT as an adjunct to standard antiviral agents to improve virological outcomes.
- Other names
- IMTFecal microbiota transplantationFMTIntestinal microbiota transplant
Beyond the preview
Go deeper on intestinal microbiota transplantation (Zhongshan Hospital Xiamen University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intestinal microbiota transplantation (Zhongshan Hospital Xiamen University).